These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 33521076)

  • 41. The novel zoonotic COVID-19 pandemic: An expected global health concern.
    Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
    J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.
    Li Y; Wang H; Tang X; Fang S; Ma D; Du C; Wang Y; Pan H; Yao W; Zhang R; Zou X; Zheng J; Xu L; Farzan M; Zhong G
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2).
    Lee JH; Choi M; Jung Y; Lee SK; Lee CS; Kim J; Kim J; Kim NH; Kim BT; Kim HG
    Biosens Bioelectron; 2021 Jan; 171():112715. PubMed ID: 33099241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
    Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
    Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.
    Abd El-Aziz TM; Stockand JD
    Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS.
    Fathi M; Vakili K; Deravi N; Yaghoobpoor S; Ahsan E; Mokhtari M; Moshfeghi M; Vaezjalali M
    Przegl Epidemiol; 2020; 74(2):276-289. PubMed ID: 33112124
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
    Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Coronavirus Disease 2019: Coronaviruses and Blood Safety.
    Chang L; Yan Y; Wang L
    Transfus Med Rev; 2020 Apr; 34(2):75-80. PubMed ID: 32107119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.
    Sharma A; Tiwari S; Deb MK; Marty JL
    Int J Antimicrob Agents; 2020 Aug; 56(2):106054. PubMed ID: 32534188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human cell receptors: potential drug targets to combat COVID-19.
    Raghav PK; Kalyanaraman K; Kumar D
    Amino Acids; 2021 Jun; 53(6):813-842. PubMed ID: 33950300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins.
    Xiao K; Zhai J; Feng Y; Zhou N; Zhang X; Zou JJ; Li N; Guo Y; Li X; Shen X; Zhang Z; Shu F; Huang W; Li Y; Zhang Z; Chen RA; Wu YJ; Peng SM; Huang M; Xie WJ; Cai QH; Hou FH; Chen W; Xiao L; Shen Y
    Nature; 2020 Jul; 583(7815):286-289. PubMed ID: 32380510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular evolution and phylogenetic analysis of SARS-CoV-2 and hosts ACE2 protein suggest Malayan pangolin as intermediary host.
    Lopes LR; de Mattos Cardillo G; Paiva PB
    Braz J Microbiol; 2020 Dec; 51(4):1593-1599. PubMed ID: 32592038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
    Noor R
    Arch Microbiol; 2021 Jul; 203(5):1943-1951. PubMed ID: 33682075
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting Crucial Host Factors of SARS-CoV-2.
    Tharappel AM; Samrat SK; Li Z; Li H
    ACS Infect Dis; 2020 Nov; 6(11):2844-2865. PubMed ID: 33112126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.